Jefferies Group Analysts Cut Earnings Estimates for UroGen Pharma (URGN)

UroGen Pharma (NASDAQ:URGN) – Investment analysts at Jefferies Group cut their Q2 2018 earnings per share estimates for UroGen Pharma in a research note issued on Wednesday, May 16th. Jefferies Group analyst M. Andrews now anticipates that the company will earn ($0.90) per share for the quarter, down from their previous estimate of ($0.88). Jefferies Group has a “Buy” rating on the stock. Jefferies Group also issued estimates for UroGen Pharma’s Q3 2018 earnings at ($0.99) EPS, Q4 2018 earnings at ($1.18) EPS, FY2018 earnings at ($3.89) EPS, FY2019 earnings at ($4.57) EPS, FY2020 earnings at ($3.44) EPS, FY2021 earnings at ($2.29) EPS and FY2022 earnings at ($0.03) EPS.

UroGen Pharma (NASDAQ:URGN) last issued its earnings results on Tuesday, May 15th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.15). The firm had revenue of $0.48 million during the quarter.

Other equities research analysts have also issued research reports about the company. UBS raised UroGen Pharma from a “market perform” rating to an “outperform” rating in a research report on Wednesday, April 4th. Oppenheimer reissued a “buy” rating on shares of UroGen Pharma in a research report on Thursday, March 22nd. Zacks Investment Research raised UroGen Pharma from a “sell” rating to a “hold” rating in a research report on Tuesday. Cowen reissued a “buy” rating on shares of UroGen Pharma in a research report on Tuesday. Finally, ValuEngine raised UroGen Pharma from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $45.50.

Shares of UroGen Pharma opened at $62.04 on Friday, according to Marketbeat Ratings. UroGen Pharma has a fifty-two week low of $61.05 and a fifty-two week high of $61.50.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. DSAM Partners London Ltd increased its position in UroGen Pharma by 83.2% during the fourth quarter. DSAM Partners London Ltd now owns 136,500 shares of the company’s stock worth $5,079,000 after buying an additional 62,000 shares during the period. Deutsche Bank AG increased its position in UroGen Pharma by 209.4% during the fourth quarter. Deutsche Bank AG now owns 50,667 shares of the company’s stock worth $1,885,000 after buying an additional 34,291 shares during the period. Clal Insurance Enterprises Holdings Ltd acquired a new position in UroGen Pharma during the fourth quarter worth approximately $166,000. Two Sigma Investments LP acquired a new position in UroGen Pharma during the fourth quarter worth approximately $277,000. Finally, Spark Investment Management LLC increased its position in UroGen Pharma by 90.6% during the fourth quarter. Spark Investment Management LLC now owns 70,700 shares of the company’s stock worth $2,630,000 after buying an additional 33,600 shares during the period. 53.00% of the stock is currently owned by institutional investors.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

Earnings History and Estimates for UroGen Pharma (NASDAQ:URGN)

Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply